1. Home
  2. BLNK vs CCCC Comparison

BLNK vs CCCC Comparison

Compare BLNK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.80

Market Cap

89.3M

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.03

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
CCCC
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.3M
240.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BLNK
CCCC
Price
$0.80
$2.03
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$2.13
$7.25
AVG Volume (30 Days)
7.1M
2.0M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,631,000.00
$30,108,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$17.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.09
52 Week High
$2.65
$4.26

Technical Indicators

Market Signals
Indicator
BLNK
CCCC
Relative Strength Index (RSI) 27.56 34.04
Support Level $0.77 $2.00
Resistance Level $0.85 $2.69
Average True Range (ATR) 0.09 0.18
MACD -0.02 -0.07
Stochastic Oscillator 3.83 3.55

Price Performance

Historical Comparison
BLNK
CCCC

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: